Zacks.com announces that Nadine Wong highlights: Genzyme.CHICAGO -- Nadine Wong, editor of the BioTech Stock Report newsletter, explains that Genzyme (Nasdaq:GENZ) has been beaten up, despite its positioning for long-term growth. Click here for the full story exclusively on Zacks.com: http://at.zacks.com/?id=84 Highlights from the March 20 Featured Expert column by Nadine Wong include: Calling Bottom Lately, shares of Genzyme (Nasdaq:GENZ) have been beaten up, despite the fact that Genzyme is well positioned for long-term growth. The 2006 top-line growth will be derived from Renagel, which should benefit significantly from the availability of Medicare Part D, which looks to lead a strong prescription growth. In the coming months the publication of Renagel's DCOR DCOR Defense Committee On Research DCOR Division Central Office of Record DCOR Data Control Resources data in a peer-reviewed journal peer-reviewed journal Refereed journal Academia A professional journal that only publishes articles subjected to a rigorous peer validity review process. Cf Throwaway journal. should boost awareness of the drug. Renagel is approved for the control of serum phosphorus in patients with chronic kidney disease Chronic kidney disease (CKD), also know as chronic renal disease, is a progressive loss of renal function over a period of months or years through five stages. Each stage is a progression through an abnormally low and progressively worse glomerular filtration rate, which is on hemodialysis hemodialysis /he·mo·di·al·y·sis/ (-di-al´i-sis) removal of certain elements from the blood by virtue of the difference in rates of their diffusion through a semipermeable membrane while being circulated outside the body; the process . Investors should pay particularly close attention to Myozyme the enzyme replacement therapy Enzyme replacement therapy is a medical treatment replacing an enzyme in patients in whom that particular enzyme is deficient or absent. Usually this is done by giving the patient an intravenous (IV) infusion containing the enzyme. for treating Pompe's disease Pom·pe's disease n. See type 2 glycogenosis. Pompe's disease see bovine generalized glycogenosis, glycogenosis type I. . With a PDUFA PDUFA Prescription Drug User Fee Act of 1992 (USA) date of April 28, 2006, Nadine Wong and her team anticipate approval and a launch of the product shortly after. Other ongoing initiatives are Campath for multiple sclerosis, televomer carbonate for C. difficile-associated diarrhea, DX88 for hereditary angioedema Hereditary angioedema A complement deficiency characterized by lymphatic vessel blockages that cause temporary swelling (edema) of areas of the skin, mucous membranes, and, sometimes, internal organs. Mentioned in: Complement Deficiencies , and Synvisc for hip pain. Read Nadine Wong's complete commentary by clicking: http://at.zacks.com/?id=85 About Zacks Featured Experts Successful investing requires professional advice from knowledgeable experts who can help investors achieve their financial goals in good markets and improve their portfolios, especially in bad ones. That is why Zacks Investment Research Zacks Investment Research A firm that compiles earnings estimates and brokerage firm investment recommendations for thousands of publicly traded firms. has assembled the best investment experts in the business to offer their powerful advisory newsletters on all the major investment topics: Stocks, Mutual Funds, Bonds, Options, Futures etc. Additional recommendations from Zacks.com Featured Experts are highlighted in the free investment newsletter, Profit from the Pros. Each issue highlights several Featured Experts in this free e-mail See Internet e-mail service. newsletter. Register for a free subscription to "Profit from the Pros" at: http://at.zacks.com/?id=86 About Zacks Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=87 Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion